Preclinical Evaluation of Lentinan in Animal Models

  • Goro Chihara
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 166)


Lentinan obtained from the fruit-body of Lentinus edodes, the most popular edible mushroom in Japan, is a fully purified β-1,6;β-1,3-D-glucan, and its physicochemical properties are strictly characterized (1-3). This polysaccharide has prominent antitumor activity in syngeneic and even autologous hosts, and its immunopharmacological characteristics are well defined as T-cell oriented immunopotentiators different from the well-known immunostimulants such as BCG, C. parvum, LPS or levamisole. Lentinan appears to represent an unique class of immunological adjuvant and has only little toxic side effects. Therefore, lentinan is worth considering as one of the most useful immunopotentiators for cancer patients, and this article concerns preclinical evaluation of lentinan in experimental and animal models for cancer immunotherapy in humans.


Lewis Lung Cancer Syngeneic Tumor Syngeneic Host Mouse Tuberculosis National Cancer Center Research Institute 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chihara, G., J. Hamuro, Y. Y. Hamuro, Y. Arai and F. Fukuoka. 1970. Fractionation and purification of the polysaccharides with marked antitumour activity, especially lentinan, from Lentinus edodes (Berk.) Sing., an edible mushroom. Cancer Res. 30: 2776.PubMedGoogle Scholar
  2. 2.
    Chihara, G. 1981. The antitumour polysaccharide lentinan: An overview, p. 1. In T. Aoki et al. (eds.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.Google Scholar
  3. 3.
    Hamuro, J., and G. Chihara. 1982. Iuuuunopotentiation by lentinan and its immunopharmacology. Chapter 14. In J. W. Hadden, A. Szentivanyi and J. R. Battisto (eds.), The pharmacology of the reticuloendothelial system. Plenum Press, New York, N.Y.Google Scholar
  4. 4.
    Zâkâny, J., G. Chihara and J. Fachet. 1980. Effect of lentinan on tumour growth in marine allogeneic and syngeneic hosts. Int. J. Cancer 25: 371.PubMedCrossRefGoogle Scholar
  5. 5.
    Shiio, T., and Y. Yugari. 1981. The antitumour effect of lentinan and tumour recognition in mice p. 29. In T. Aoki et al. (ads.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.Google Scholar
  6. 6.
    Hamada, C. 1981. Inhibitory effect of lentinan on the tumourigenesis of adenovirus type-12 in mice p. 76, In T. Aoki et al. (eds.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.Google Scholar
  7. 7.
    Kanaí, K., E. Kondo, P. J. Jacques and G. Chihara. 1980. Immunopotentiating effect of fungal glucans as related by frequency limitation of post chemotherapy relapse in experimental mouse tuberculosis. Jap. J. Med. Sci. & Biol. 33: 283.Google Scholar
  8. 8.
    Chang, K. S. S. 1981. Lentinan-mediated resistance against VSV-encephalitis, Abelson virus-induced tumour, and trophoblastic tumour in mice, p. 88. In T. Aoki et al. (eds.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.Google Scholar
  9. 9.
    Byrum, J. E., A. Sher, J. DiPietro and F. von Lichitenberg. 1979. Potentiation of Shistosoma granuloma by lentinan, A T-cell adjuvant. Am. J. Pathol. 94: 201.Google Scholar
  10. 10.
    Haba, S., T. Hamaoka, K. Takatsu and M. Kitagawa. 1976. Selective suppression of T-cell activity in tumour bearing mice and its improvement by lentinan. Int. J. Cancer 18: 93.PubMedCrossRefGoogle Scholar
  11. 11.
    Maeda, Y. Y., and G. Chihara. 1973. The effect of neonatal thymectomy on the antitumour activity of lentinan and their effects on various immune responses. Int. J. Cancer 11: 153.PubMedCrossRefGoogle Scholar
  12. 12.
    Hamuro, J., M. Röllinghof and H. Wagner. 1980. Induction of cytotoxic PE-cells by T-cell immune adjuvant of the 8–1,3-glucan type lentinan and its analogues. Immunology 39: 551.PubMedGoogle Scholar
  13. 13.
    Maeda, Y. Y., G. Chihara and K. Ishimura. 1974. Unique increase of serum protein components and action of antitumour polysaccharides. Nature (London) New Biol. 252: 250.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Goro Chihara
    • 1
  1. 1.National Cancer Center Research InstituteTokyo, 104Japan

Personalised recommendations